ScrutarSign up free

ABBV SEC Filings

SEC filings for ABBV. Annual and quarterly reports, 8-K events,
Form 4 insider filings and 13D/G stake disclosures.

All10-K10-Q8-KForm 413D/GLast 12 months
FormFiledAccession
4Donoghoe NicholasEVP, CHIEF BUS/STRAT OFFICERAug 18, 2026EDGAR
8-KAug 18, 2026EDGAR
8-KAug 5, 2026EDGAR
10-QAug 3, 2026EDGAR
8-KJul 31, 2026EDGAR
8-KAIAbbVie disclosed that Q2 2026 GAAP and adjusted non-GAAP earnings will include $291 million in pre-tax acquired IPR&D and milestones expense, reducing diluted EPS by $0.17.Jul 6, 2026EDGAR
8-KAIAbbVie disclosed a definitive agreement to acquire Apogee Therapeutics, announced via a joint press release and investor presentation on June 22, 2026.Jun 22, 2026EDGAR
4FALK THOMAS JMay 12, 2026EDGAR
4WADDELL FREDERICK HMay 12, 2026EDGAR
4Roberts Rebecca BMay 12, 2026EDGAR
4RAPP EDWARD JMay 12, 2026EDGAR
4Quaggin Susan EMay 12, 2026EDGAR
4MEYER MELODY BMay 12, 2026EDGAR
4Hart Brett JMay 12, 2026EDGAR
4FREYMAN THOMAS CMay 12, 2026EDGAR
4Davis Jennifer L.May 12, 2026EDGAR
4BURNSIDE WILLIAM H.L.May 12, 2026EDGAR
4AUSTIN ROXANNE SMay 12, 2026EDGAR
8-KMay 12, 2026EDGAR
10-QMay 8, 2026EDGAR
SC 13GVanguard Capital ManagementApr 29, 2026EDGAR
8-KAIAbbVie Inc. filed an 8-K announcing its financial results for the first quarter ended March 31, 2026, via a press release furnished as Exhibit 99.1.Apr 29, 2026EDGAR
8-KApr 3, 2026EDGAR
SC 13G/AamendedVANGUARD GROUP INCMar 26, 2026EDGAR
4/APurdue David RyanSVP, ControllerMar 11, 2026EDGAR
4Purdue David RyanSVP, ControllerMar 6, 2026EDGAR
4Crum Demetris DEVP, CHIEF HR OFFICERMar 6, 2026EDGAR
8-KMar 4, 2026EDGAR
4Thakkar RoopalEVP, R&D and CSOMar 3, 2026EDGAR
4Michael Robert A.CHAIRMAN OF THE BOARD AND CEOMar 3, 2026EDGAR
4Stewart Jeffrey RyanEVP, CHIEF COMMERCIAL OFFICERMar 3, 2026EDGAR
4Siatis Perry CEVP, GC AND SECRETARYMar 3, 2026EDGAR
4Reents Scott TEVP, CHIEF FINANCIAL OFFICERMar 3, 2026EDGAR
4SALEKI-GERHARDT AZITAEVP, CHIEF OPERATIONS OFFICERMar 3, 2026EDGAR
4Donoghoe NicholasEVP, CHIEF BUS/STRAT OFFICERMar 3, 2026EDGAR
4Siatis Perry CEVP, GC AND SECRETARYFeb 27, 2026EDGAR
8-KFeb 26, 2026EDGAR
4Thakkar RoopalEVP, R&D and CSOFeb 20, 2026EDGAR
4Purdue David RyanSVP, ControllerFeb 20, 2026EDGAR
4Stewart Jeffrey RyanEVP, CHIEF COMMERCIAL OFFICERFeb 20, 2026EDGAR
4Siatis Perry CEVP, GC AND SECRETARYFeb 20, 2026EDGAR
4SALEKI-GERHARDT AZITAEVP, CHIEF OPERATIONS OFFICERFeb 20, 2026EDGAR
4Crum Demetris DEVP, CHIEF HR OFFICERFeb 20, 2026EDGAR
4Donoghoe NicholasEVP, CHIEF BUS/STRAT OFFICERFeb 20, 2026EDGAR
4Reents Scott TEVP, CHIEF FINANCIAL OFFICERFeb 20, 2026EDGAR
4Michael Robert A.CHIEF EXECUTIVE OFFICERFeb 20, 2026EDGAR
10-KFeb 20, 2026EDGAR
8-KAIAbbVie Inc. announced its financial results for the fourth quarter and full year ended December 31, 2025 via a press release furnished as an exhibit to this 8-K.Feb 4, 2026EDGAR
8-KAIAbbVie disclosed that its Q4 2025 GAAP and adjusted non-GAAP earnings will include $1.3 billion of pre-tax acquired IPR&D and milestones expense, reducing diluted EPS by $0.71.Jan 7, 2026EDGAR
10-QNov 4, 2025EDGAR
8-KAIAbbVie Inc. announced its financial results for the third quarter ended September 30, 2025 via press release furnished as an exhibit to this 8-K.Oct 31, 2025EDGAR
8-KAIAbbVie disclosed preliminary Q3 2025 results reflecting a $2.7 billion pre-tax acquired IPR&D and milestones expense, which will reduce GAAP and adjusted diluted EPS by $1.50.Oct 3, 2025EDGAR
8-KAIAbbVie announced settlement of patent litigation with all generic manufacturers that had filed ANDAs for generic upadacitinib (RINVOQ) tablets.Sep 11, 2025EDGAR

SEC filings for companies related to ABBV

PFEPFIZER INCLLYELI LILLY & CoJNJJOHNSON & JOHNSONMCDMCDONALDS CORPXOMExxonMobil Holdings Corp

Never miss a ABBV filing.

Get an email when ABBV files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.

Free foreverNo account requiredOne-click unsubscribe

Protected by reCAPTCHA. Privacy & Terms

Source: SEC EDGAR.